Drug, bio-affecting and body treating compositions inventions 03/08

20080075671 - Intranasally administering curcumin to the brain to treat alzheimer's disease: The present invention relates to intranasally administering a pharmaceutical composition comprising curcumin to an upper third of a nasal cavity of the mammal, wherein the curcumin is absorbed through a nasal mucosa and transported to the brain of the mammal.... Agent: Philip S. Johnson Johnson & Johnson

20080075674 - Cough suppressor: A cough suppressor according to the present invention includes a chewable inner layer having a predetermined flavor. Preferably, the inner layer is chewing gum. The cough suppressor also includes an active layer situated outside the inner layer and that includes a cough suppressant. In addition, a buffer layer completely separates... Agent: Harshaw Research, Inc.

20080075677 - Antioxidant complex and a cosmetic and pharmaceutical composition comprising said complex: The present invention relates to an antioxidant complex comprising from 0.000001% to 40.00000% by weight of at lest one cinnamiA acid, from 0.000001% to 40.00000% by weight of at least one carotenoid, from 0.000001% to 99.999998% by weight of vitamin E, and a cosmetically and pharmaceutically acceptable a carrier, all... Agent: Alston & Bird LLP

20080075679 - Compositions containing dark glitter: The invention relates to compositions containing glitter containing dark colorant as well as to methods of applying such compositions to keratin materials and kits containing such compositions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080075725 - Novel immunointeractive molecules and uses thereof: The present invention relates generally to molecules such as peptides, polypeptides and proteins which interact immunologically with T lymphocytes in subjects having peanut allergy, or allergy to other tree nuts, and genetic sequences encoding same. These molecules are preferentially immunointeractive with T cells in subjects having an allergy to the... Agent: Scully Scott Murphy & Presser, PC

20080075727 - Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies: Methods of therapy for B-cell malignancies are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a... Agent: Novartis Vaccines And Diagnostics Inc

20080075728 - Combination therapies of hmgb and complement inhibitors against inflammation: Compositions and methods are disclosed for treating a condition characterized by activation of an inflammatory cytokine cascade in a patient. The compositions comprise an HMGB A box and an inhibitor of complement biological activity, and/or an antibody that binds an HMGB polypeptide or biologically active fragment thereof and an inhibitor... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080075729 - Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders: The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The mammal may be selected from dogs, cats, sheep, goats, cattle, horses, pigs, mice, humans and non-human primates. The method comprises suppressing or otherwise inhibiting... Agent: Fish & Richardson P.C.

20080075786 - Antimicrobial agents derived from cream: Methods for interfering with the growth of fungi by exposing the fungi to an antimicrobial agent derived from cream, and more particularly, to methods for treating human fungal pathogens such as Candida albicans and Aspergillus fumigatus, through exposing the fungi to free fatty acids with antimicrobial activity derived from cream.... Agent: Gordon & Rees LLP

20080075787 - Therapeutic agent for ophthalmic diseases: A therapeutic agent for ophthalmic diseases containing Laennec (trade name) as an active ingredient. Laennec, the active ingredient, exhibits a therapeutic effect on a wide variety of ophthalmic diseases by increasing tears and the like and is highly safe even though it is an animal-derived component. Therefore, the therapeutic agent... Agent: Birch Stewart Kolasch & Birch

20080075788 - Diammonium phosphate and other ammonium salts and their use in preventing clotting: The present invention relates to products, methods, and processes of various ammonium salts and their use as anti-coagulants.... Agent: Kilpatrick Stockton LLP - 55461

20080075789 - Genes differentially expressed in bipolar disorder and/or schizophrenia: This invention provides molecular markers that are prognostic and/or diagnostic for a psychiatric disorder. In particular, genes are identified whose expression is altered in schizophrenia and/or bipolar disorder thereby providing prognostic and diagnostic markers for the disorder. In addition genes are identified whose dysregulation provides markers that allow diagnostic distinction... Agent: Beyer Weaver LLP

20080069773 - Novel sodium channel: Novel sodium channel nucleic acids and polypeptides are disclosed herein. Methods of using the novel nucleic acids and polypeptides are also disclosed.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP (formerly Kirkpatrick&lockhart Nicholson Graham)

20080069777 - Conformation specific antibodies: The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between... Agent: Gosz And Partners LLP

20080069776 - Histofluorescent stain for endoscopy: e

20080069781 - Treatment of periodontal disease with photosensitizers: A method and composition is disclosed for treating oral diseases, including inflammatory periodontal disease, by utilizing photosensitizing compounds in long term effect or timed release formulations, including local highly concentrated formulations in biofilms on teeth and implants and oral wounds as well as periodontal pockets, and activating the photosensitizers with... Agent: Bolesh J. Skutnik Phd, Jd

20080069782 - Method of inhibiting bacterial growth and biofilm formation with natural quorum sensing peptides: Methods for selectively manipulating a growth rate of a selected bacterium comprising the step of contacting the selected bacterium with a predetermined amount of a quorum sensing molecule to affect a change in the growth rate of the selected bacterium, wherein the quorum sensing molecule is species specific, and the... Agent: Hogan & Hartson L.L.P.

20080069783 - Oral cavity cleaning composition: The present invention provides an oral cavity cleaning composition, comprising 35˜50 parts by weight of tea leaves extract, 10˜25 parts by weight of Stevia leaf extract, 10˜25 parts by weight of lemon extract, 10˜15 parts by weight of mint leaf extract, 10˜20 parts by weight of Lonicerae Flos extract, 20˜30... Agent: Birch Stewart Kolasch & Birch

20080069788 - Basic aluminium halogenide complexes: Basic aluminum halide complexes obtained by reaction of aluminum metal with hydrohalic acid and an organic acid, where either the aluminum metal is dissolved in a mixture of hydrohalic acid and organic acid, or the aluminum metal is firstly dissolved in the hydrohalic acid and then the organic acid is... Agent: Clariant Corporation Intellectual Property Department

20080069791 - Means for stimulation and activation of hair growth by il-15: The present invention relates to the use of IL-15 polynucleotides, polypeptides or compounds which bind to an antibody which specifically recognizes the IL-15 polypeptide or which specifically bind to an IL-15 receptor alpha chain for the preparation of a composition for stimulating hair growth or for treating, preventing and/or ameliorating... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069806 - Method of screening for substances useful for transdifferentiation of microglia into neurons: According to the present invention, there is provided a method of screening for a substance useful for transdifferentiation of microglia into neurons, a method of producing neurons, and a method of treating a neurologic disorder.... Agent: Oliff & Berridge, PLC

20080069805 - Use of stem cells to cure genetic diseases in humans cure for sickle cell anemia: Transplant of donor perfectly matched HLA hematopoietic stem cell to cure Sickle cell anemia and other anemia such as leukemia. Sterilized In vivo transplantation of clinically adequate quantities of antibiotic protected HLA vector/or insertion corrected chimera stem cells, and switching protein. Stem cells can be transfected for Hbg SS, and... Agent: Bruce M. Williams

20080069808 - Ec sod and cell transducing ec sod and use thereof: The present invention relates to an EC SOD, a cell-transducing EC SOLD, and the use thereof. More particularly, the present invention relates to an EC SOD, an EC SOD fusion protein enhanced Cell-transduction ability, and the use thereof for preventing or treating skin diseases.... Agent: Buchanan, Ingersoll & Rooney PC

20080069770 - Nucleotide sequence coding for variable regions of beta chains of human t lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses: The present invention relates to new nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080069771 - Oxygenated polymerized hemoglobin solutions and their uses for tissue visualization: An oxygenated Hemoglobin (Hb) solution includes from about 10 g to about 250 g of polymerized Hb per liter of solution. About 80% by weight, or greater, of the polymerized Hb of the oxygenated hemoglobin solution is oxyhemoglobin. About 18% by weight, or less, of the polymerized Hb has a... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20080069772 - Treatment of transformed or infected biological cells: The present invention relates to a therapeutic or/and diagnostic substance. Furthermore it relates to an expression vector, to a composition comprising the afore-mentioned substance or/and the afore-mentioned expression vector, a method for diagnosing a tumor disease or/and an infectious disease in a living being, as well as to a method... Agent: Marshall, Gerstein & Borun LLP

20080069774 - Proteomic antisense molecular shield and targeting: The present invention provides compositions and methods for shielding and directing agents to biological targets in cellular systems for therapeutic, prophylactic, and diagnostic uses. Vascular devices are also provided which have coated surfaces that contain proteomic antisense, as well as therapeutic and other biological agents attached thereto.... Agent: Millen, White, Zelano & Branigan, P.C.

20080069778 - Polymer-encapsulated microspheres: A polymer-encapsulated phospholipid microsphere, comprising a plurality of lipid molecules disposed in a liquid and arranged to define an enclosed space, and one or more polymers partially or completely encapsulating that enclosed space. The one or more polymers may be functionalized with either a therapeutic agent and/or a targeting ligand... Agent: Dale F. Regelman

20080069775 - Humanization of an anti-carcinoembryonic antigen anti-idiotype antibody as a tumor vaccine and for targeting applications: A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotype also can be used as an immunogenic vaccine.... Agent: Faegre & Benson LLP Patent Docketing

20080069779 - Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof: Vitamin and flavonoid containing compositions are provided that are stable to degradation. Stabilized compositions include one or more features including a hygroscopic solvent at a sufficient concentration to provide an Aw value of the hygroscopic vitamin and or flavonoid containing composition of less than 0.9, antioxidant flavonoids that are preferentially... Agent: Wilmerhale/boston

20080069780 - High concentration single phase gycol aerosol air sanitizer with dimethyl ether propellant/solvent: Improved single-phase aerosol spray air sanitizers and deodorizers are disclosed. The preferred active ingredient for the air sanitization is a high concentration of triethylene glycol (TEG), in a single-phase aerosol formulation made possible by the use of dimethyl ether (DME) as a propellant. The combination of TEG and DME enables... Agent: S.c. Johnson & Son, Inc.

20080069785 - Pest-control compositions, and methods and products utilizing same: Pest-combating compositions containing pest-control actives are formulated for sustained pest-combating efficacy, utilizing actives fatty acids, undecanone, and/or soy methyl ester in varying combinations. Pest-combating includes both repellency and killing of pests. In specific formulations, the pest-combating composition includes any one, two or three of the active agents soy methyl ester,... Agent: Intellectual Property / Technology Law

20080069784 - Regulation of mammalian keratinous tissue using skin and/or hair care actives: Personal care compositions containing an active selected from the group consisting of Lauryl p-Cresol Ketoxime, Bis-abolol and ginger extract, 4-(1-Phenylethyl)1,3-benzenediol, Lupin (Lupinus albus) oil & wheat (Triticum vulgare) germ oil unsaponifiables, Hydrolyzed lupin protein, Extract of L-lysine and L-arginine peptides, Oil soluble vitamin C, Evodia rutaecarpa fruit extract, Zinc pidolate... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080069786 - Polycondensate, composition, treatment process, and preparation process: Polycondensate, composition containing it, especially a nail varnish composition, and process for preparation. The polycondensate may be obtained by reacting: a polyol comprising 3 to 6 hydroxyl groups; a saturated or unsaturated non-aromatic monocarboxylic acid; an aromatic monocarboxylic acid containing 7 to 11 carbon atoms; and a saturated or unsaturated,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069787 - Acidic composition for external use, and agent for accelerating penetration into skin or the like of cosmetic preparation, hair-growing agent and preparation for external use each containing the composition: An acidic composition for external use which contains an acidic poly saccharide and water as essential ingredients, and an agent for accelerating the penetration into skin or the like of a cosmetic preparation, hair-growing agent or preparation for external use, each containing the composition. The composition is easy to manufacture,... Agent: Watchstone P+d, PLC

20080069789 - N-alkylheteroaryl secondary para-phenylenediamine and composition comprising such a para-phenylenediamine: The present disclosure is directed to a family of N-alkylheteroaryl secondary para-phenylenediamines, to their preparation, and to a cosmetic composition for dyeing keratin fibers, for example, human keratin fibers such as the hair, comprising, in a suitable dyeing medium, at least one N-alkylheteroaryl secondary para-phenylenediamine. Further disclosed herein is a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080069790 - Pre-shave preparation with enhanced lubricity using carboxy silicone polymer: Pre-shave compositions to lubricate skin during electric shaving that comprise at least one carboxy silicone polymer and a volatile component to serve as a carrier to the polymer. The pre-shave composition lubricates the skin to reduce skin friction between the electric razor and the skin surface, provides a closer shave,... Agent: St. Onge Steward Johnston & Reens, LLC

20080069792 - Polyamino acid derivatives and use thereof in compositions for treating keratin fibers: The invention concerns the use in a cosmetic composition of at least a poly-aminoacid of general formula (1) in which X is —O—, —S— or —NR3; R1 represents in particular a hydrogen atom or a C1-C40 alkyl radical; R2 represents in particular a hydrogen atom or an optionally substituted alkyl... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080069793 - Surfactant-free cosmetic, dermatological and pharmaceutical agents: The invention provides surfactant-free cosmetic, pharmaceutical, and dermatological compositions comprising at least one copolymer obtainable by free-radical copolymerization of A) acryloyldimethyltaurine and/or acryloyldimethyltaurates, B) if desired, one or more further olefinically unsaturated, noncationic comonomers, C) if desired, one or more olefinically unsaturated, cationic comonomers, D) if desired, one or more... Agent: Clariant Corporation Intellectual Property Department

20080069794 - Procyanidin-l-arginine combinations: The invention relates to compositions having an enhanced level of cocoa polyphenol and L-arginine which are effective in inducing vasodilation. The invention also relates to products including foods such as confectionary and pet foods, comprising cocoa polyphenols and L-arginine which are useful for inducing vasodilation.... Agent: Nada Jain, P.C.

20080069795 - Amelioration of drug-induced toxicity: Kidney toxicity which is induced by cisplatin and other therapeutic and diagnostic agents, limits the effectiveness of the therapy or diagnosis. Modulation or depletion of T cells ameliorates the toxicity, permitting the use of cisplatin at levels and for durations which treat cancers more effectively. Modulation and depletion can be... Agent: Banner & Witcoff, Ltd.

20080069796 - Low dose treatment with an interleukin-11 analog: The invention relates to an analog of human interleukin-11 (IL-11) polypeptide which has increased potency and stability relative to wild-type IL-11 and which is therapeutically effective at low doses.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080069797 - Rapamycin and il-10 for the treatment of immune diseases: The invention discloses a combined preparation containing IL-10 and rapamycin, able to induce immunosuppression and antigen-specific immune tolerance, and the use thereof in the treatment of diseases involving an excessive, dysfunctional or uncontrolled immune responses mediated by T cells.... Agent: Young & Thompson

20080069798 - Use of il-22 for the treatment of conditions of metabolic disorders: The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetes. IL-22 may also be used in combination with insulin for diabetes.... Agent: EagleIPLimited

20080069799 - Use of il-22 for the treatment of conditions of metabolic disorders: The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetes. IL-22 may also be used in combination with insulin for diabetes.... Agent: EagleIPLimited

20080069800 - System for high production of natural and personalized interferons: The present invention generally relates to systems and methods for the production of high amounts of personalized interferons (IFNs), which are IFNs produced from the cells of the patient to whom the IFN is to be administered, for therapeutic and research uses. The system can also be used to produce... Agent: Sheridan Ross PC

20080069801 - Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications: Biopolymer beads and hydrogels are useful in the remodeling, repair and reconstruction of the heart, as well as in modification of electrical conduction in the heart. Various types of beads are useful, including beads comprising a core of alginate polymers which may or may not be bonded to peptides; beads... Agent: Cyr & Associates, P.A.

20080069803 - Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions vectors: The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle... Agent: Robins & Pasternak

20080069802 - Modified virus: Modified viral particles wherein the viral particles, typically adenoviral particles, are modified by glycosylation and the use of the modified viral particles to deliver heterologous nucleic acid to cells. Also disclosed are pharmaceutical compositions comprising the same and method of treatment using the same.... Agent: Baker Donelson Bearman Caldwell & Berkowitz, PC

20080069804 - Alphavirus replicon packaging constructs: Provided herein are modified, functional 5′ amplification sequences that are defective packaging signals. Also provided are compositions and methods comprising these modified 5′ amplification sequences.... Agent: Novartis Vaccines And Diagnostics Inc.

20080069807 - Cell-derived microparticles as hemostatic agents for control of hemorrhage and treatment of bleeding disorders: Compositions comprising membrane-derived and synthetic microparticles that induce platelet aggregation and are useful for treating bleeding disorders, particularly those involving platelet dysfunction. Microparticles include endothelial derived microparticles (EMP), platelet derived microparticles (PMP), erythrocyte derived microparticles (RMP), and synthetic microparticles (SMP), and are used to treat disorders such as thrombocytopenia caused... Agent: Venable LLP

20080069809 - Compositions and methods for the diagnosis and treatment of cancer: The present invention relates generally to the fields of diagnosis and treatment of cancer. More particularly, the present invention provides a method of determining the likely or relative sensitivity of cancer cells to a particular anti-cancer agent prior to or during anti-cancer treatment. Therapeutic protocols for the treatment of cancer... Agent: The Mccallum Law Firm, P. C.

20080069810 - Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides: The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide, and TAFI or a TAFI-related polypeptide, and the use thereof for treating bleeding episodes.... Agent: Novo Nordisk, Inc. Patent Department

20080069811 - Fsh and fsh receptor modulator compositions and methods for inhibiting osteclastic bone resorption and bone loss in osteoporosis: The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders.... Agent: Crowell & Moring Intellectual Property Group

20080069812 - Iap bir domain binding compounds: e

20080069813 - Isolated bovine igg heavy chain protein and its use as an antimicrobial: A new protein derived from acid hydrolyzed IgG concentrate which has a molecular weight of about 55,000, and is activated by heat within the defined narrow temperature range provides resulting product that has a protective mechanism for bacterial and viral invasion of living cells.... Agent: Schwegman, Lundberg & Woessner, P.A.

20080069815 - Anti-osteopontin antibody and use thereof: An anti-osteopontin antibody which inhibits the binding of an integrin recognizing RGD sequence to osteopontin or its fragment, and which inhibits the binding of an integrin recognizing SVVYGLR sequence or sequence equivalent thereto to osteopontin or its fragment. This antibody is useful in remedies for autoimmune diseases, remedies for rheumatism... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069817 - Heteroaryl-fused pyrimidinyl compounds as anticancer agents: Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with... Agent: Chiron Corporation Intellectual Property - R440

20080069816 - Humanized anti-cea t84.66 antibody and uses thereof: Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to... Agent: Perkins Coie LLP

20080069814 - Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof: The present invention relates to a method for preventing, treating, or ameliorating thrombotic disorders in an animal comprising administering to the animal an active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound or the mimic thereof may be administered by HDPA so... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080069819 - Method and composition for detecting cancer by means of detection of epstein-barr virus nuclear antigen 2 coactivator p100: The present invention relates to a method for diagnosing cancer and a detection reagent based on detection of Epstein-Barr virus nuclear antigen 2 (EBNA2) coactivator p100 contained in a specimen, and a method for treating cancer by controlling expression of EBNA2 coactivator p100 protein or a gene thereof.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069818 - Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents: The present invention provides compositions and methods for increasing the amount of active Syk protein kinase in a cell. The compositions and methods are useful for increasing the efficacy of anti-neoplastic agents, such as those used to treat leukemia, and thus for treatment of cancers, including leukemias. They are also... Agent: Latimer, Mayberry & MatthewsIPLaw, LLP

20080069820 - Multispecific antibodies: The invention provides multispecific antibodies and methods of making and using such antibodies.... Agent: Clark & Elbing LLP

20080069821 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.... Agent: Johnathan Klein-evans

20080069822 - Anti-orthopoxvirus recombinant polyclonal antibody: Disclosed is an anti-orthopoxvirus recombinant polyclonal antibody comprising distinct members which in union are capable of binding at least three orthopoxvirus related antigens, a pharmaceutical composition comprising the antibody, and a method for its production. Also disclosed is a polyclonal cell line capable of producing the recombinant polyclonal antibody as... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080069823 - Attenuation of reperfusion injury: Compositions for and methods of attenuating and/or preventing ischemia-reperfusion injury (IRI) are provided. One method comprises administering to a patient in need thereof an agent that binds phosphatidylserine (PS) located on cell surfaces, i.e., PS binding agent. Another method comprises administering to an organ transplant recipient a therapeutic composition comprising... Agent: Swanson & Bratschun, L.L.C.

20080069824 - Size-variable strain-specific protective antigen for potomac horse fever: An isolated and purified antigen which is expressed by a wild-type E. risticii strain and is specific to the stain. The present invention also relates to nucleic acid constructs which encode the antigen, expression vectors, transformed host cells, and methods for producing the antigen.... Agent: Intervet Inc. Patent Department

20080069828 - Methods, kits, and antibodies for detecting parathyroid hormone: The present invention relates to novel methods and compositions useful for detecting whole parathyroid hormone at a physiological level and parathyroid fragments in a mammalian sample. Such detections may be useful to different parathyroid diseases or disorders in a subject, such as hyperparathyroidism and related bone diseases, from normal or... Agent: Morrison & Foerster LLP

20080069827 - Mirna of hsv-lat and uses thereof: This invention relates to treatment of Herpes Symplex Virus infection. Specifically, the invention relates to the use of a newly discovered miRNA in the silencing of HSV-LAT gene, which is responsible for the prevention of apoptosis of infected neuronal cells and the maintenance of latency.... Agent: Pearl Cohen Zedek Latzer, LLP

20080069825 - Multiple cpg oligodeoxynucleotides and their use to induce an immune response: Compositions including multiple oligodeoxynucleotides with a CpG motif are disclosed herein. The compositions can include either D or K type oligodeoxynucleotides. These compositions are of use in inducing an immune response in a large percentage of the individuals in a population.... Agent: Klarquist Sparkman, LLP

20080069826 - Novel genes associated with the maintenance of differentiation of smooth muscle cells: A cDNA fragment participating in the maintenance of smooth muscle differentiation was isolated using a culture system of chicken gizzard smooth muscle cells, the differential display method and the subtracted hybridization method. Using the obtained cDNA sequence as a query, cDNA sequences of Helix Research Institute (Japanese Patent Application No.... Agent: Fish & Richardson PC

20080069829 - Antigenic protein originating in malassezia: A substantially pure, isolated, antigenic protein from fungi of the genus Malassezia, characterized in that said antigenic protein has a binding ability to IgE antibodies from patients with allergoses; an antigenic fragment derived from the antigenic protein; and an antibody against the antigenic protein or fragments thereof. According to the... Agent: Birch Stewart Kolasch & Birch

20080069830 - Dna sequences, peptides, antibodies and vaccines for prevention and treatment of sars: The invention comprises novel DNA, protein, and peptide sequences and novel vaccines, therapeutics and antibodies created with the novel DNA and peptides to prevent or treat SARS by administration of recombinant proteins, synthetic peptides, recombinant viruses, recombinant bacteria, DNA plasmids, RNA plasmids, or other molecular constructs or delivery systems.... Agent: David S. Dolberg

20080069831 - Yeast-based therapeutic for chronic hepatitis c infection: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with... Agent: Sheridan Ross PC

20080069832 - Vaccines: The present invention provides a vaccine composition comprising the B subunit of Shiga toxin or an immunologically functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen, and further comprising an adjuvant, provided that when the adjuvant is solely a metal salt it is formulated... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080069833 - Yeast-based vaccines as immunotherapy: Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle... Agent: Sheridan Ross PC

20080069834 - Use of antioxidants for gene modulation: The invention provides (1) methods for modulating gene expression in senescent mammals by administering antioxidant-comprising compositions to the mammals and (2) antioxidant-comprising compositions that modulate gene expression and/or reduce the oxidative stress of such mammals.... Agent: Colgate-palmolive Company

20080069835 - Vaccine composition: The present invention relates to new, advantageous DTP-based combination vaccine formulations, and concomitantly administered combination vaccine kits. Methods of administration of these vaccines and kits are also provided.... Agent: Glaxosmithkline Corporate International Property - Uw2220

20080069837 - Composition and method for treating cancer using herpes virus: The present invention provides a herpes virus in which a non-essential gene for replication is inactivated. More particularly, the present invention provides a herpes virus in which a non-essential gene for replication present in a UL or US region is inactivated. More preferably, the non-essential gene for replication contains US3... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20080069836 - Method of using adenoviral vectors with increased immunogenicity in vivo: The invention provides a method of inducing an immune response in a mammal. The method comprises administering to the mammal an adenoviral vector comprising (a) a subgroup C fiber protein wherein a native coxsackievirus and adenovirus receptor (CAR)-binding site is disrupted, (b) a subgroup C penton base protein wherein a... Agent: Leydig Voit & Mayer, Ltd

20080069838 - Novel human virus causing severe acute respiratory syndrome (sars) and uses thereof: The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention... Agent: Dickstein Shapiro LLP

20080069839 - Isolation and characterization of the precursor virus of human sars virus: sars-associated corona virus-like virus: The present invention relates to isolation and characterization of a class of isolated novel viruses which is the precursor of the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The precursor virus which is a SARS coronavirus-like virus (“SCoV-like virus”) is identified to be morphologically and phylogenetically... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20080069840 - Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines: An immunotherapeutic strategy is disclosed that combines antigen-encoding DNA vaccine compositions combined with siRNA directed to pro-apoptotic genes, primarily Bak and Bax, the products of which are known to lead to apoptotic death. Gene gun delivery (particle bombardment) of siRNA specific for Bak and/or Bax to antigen-expressing DCs prolongs the... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080069841 - Pharmaceutical compositions containing botulinum neurotoxin a2: A composition, medicament or use, comprising or consisting of botulinum toxin type A2 and a surfactant, having one or more or all of the characteristics select from the group consisting of; (a) a much longer duration of action; (b) a much faster rate of onset of muscular paralysis; (c) a... Agent: Jacobson Holman PLLC

20080069842 - Vaccines for mycoplasma bovis and methods of use: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of... Agent: Kenyon & Kenyon LLP

20080069843 - Salmonella vaccine: The present invention relates to Salmonella bacteria. The invention also relates to methods of using Salmonella bacteria, including in vaccines based thereon that are useful for the prevention of microbial pathogenesis. Further, the invention relates to the use of such bacteria or the manufacture of such vaccines. The invention also... Agent: Trask Britt

20080069844 - Mucosal vaccine adjuvants containing bacterial flagellins as an active component: The present invention relates to mucosal vaccine adjuvants containing flagellins, the structural component of flagella, originated from Vibrio vulnificus, Salmonella typhimurium, and Listeria monocytogenes as an active component.... Agent: Sughrue Mion, PLLC

20080069846 - Protease, a gene therefor and the use thereof: The present invention relates to a protease, and more specifically to a protease derived from Aranicola proteolyticus, a gene coding for said enzyme, a gene expression system for said protease, a process for purifying the protease, and the uses of said protease in industrial applications, such as for example, detergents,... Agent: Sheridan Ross PC

20080069845 - Skin covering sheet for cosmetic preparation impregnation and process for producing the same , and face mask using sheet: A skin application sheet for being impregnated with a cosmetic preparation is provided which is suitable for a face mask and so on, and causes less irritation to skin, and has good application properties. A splittable conjugate fiber web containing at least 50% by mass of splittable conjugate fibers is... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20080069847 - Materials containing negative ions and infrared materials for promoting health: Materials and fabrics compounded with negative ions and infrared materials to promote circulation of blood, ease stress and relieve body pain.... Agent: Weiss & Weiss

20080069848 - Device, method, and use for treatment of neuropathy involving nitric oxide: A device is provided that allows for target treatment of neuropathy, such as diabetic peripheral neuropathy, or neuropathy and ulcers resulting from said neuropathy. The device comprises a nitric oxide (NO) eluting polymer arranged to contact a treatment area, such that a therapeutic dose of nitric oxide is eluted from... Agent: Knobbe Martens Olson & Bear LLP

20080069849 - Novel antimicrobial peptides: The invention relates to the use of peptides, wherein at least one amino acid residue has been substituted to improve the efficacy of the antimicrobial peptide for the manufacturing of an antimicrobial composition. The composition can be used as a pharmaceutical composition to combat microorganisms, such as bacteria, virus, fungus,... Agent: Merchant & Gould PC

20080069850 - Multicomponent bioactive intravaginal ring: Intravaginal ring devices have multicomponent drug releasing substrates loaded with at least one bioactive agent and designed to effect contraception and/or provide means to treat and/or prevent diseases caused by infectious bacteria, fungi, virus, and retroviruses, without compromising the primary function of normally occurring, useful vaginal microflora in female patients.... Agent: Leigh P. Gregory

20080069851 - Substituted n-aminomethylene sulfonamides, production and use thereof as medicaments: Disclosed are compounds of the general formula (I), with the definitions of the substituents R1 to R5, A and X being detailed in the text, and to their physiologically tolerated salts, to processes for preparing these compounds and to the use thereof as inhibitors of hormone-sensitive lipase (HSL).... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20080069853 - Antibody production method: A method of inducing the sustained release of antibodies in milk comprising the step of: a) implanting at least one antigen releasing device adjacent to, within close proximity of or within at least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue... Agent: Palmer & Dodge, LLP Kathleen M. Williams

20080069854 - Medical devices and methods of making and using: Disclosed herein are medical devices. The medical devices generally include a biocompatible nanostructured ceramic material having an average grain size dimension of about 1 nanometer to about 1000 nanometers, a strain to failure of at least about 1 percent, and a cross-sectional hardness greater than or equal to about 350... Agent: Cantor Colburn, LLP

20080069855 - Method of inhibiting the formation of adhesions and scar tissue and reducing blood loss: The present invention provides a method for inhibiting the formation of scar tissue and/or exogenous bone at a wound site in a body of a patient. The method includes administering an amount of a biologic agent to the wound site, wherein the biologic agent is synovial fluid or cerebrospinal fluid.... Agent: Paul D. Bianco: Fleit, Kain, Gibbons, Gutman, Bongini, & Bianco P.l.

20080069852 - Porous osteoimplant: The invention is directed toward porous composites for application to a bone defect site to promote new bone growth. The inventive porous composites comprise a biocompatible polymer and a plurality of particles of bone-derived material, inorganic material, bone substitute material or composite material. In certain embodiments, the porous composites are... Agent: Choate, Hall & Stewart LLP

20080069856 - Compression molding method for making biomaterial composites: A process for making an implantable material comprising a composite of a biocompatible polymer and a bioactive agent. The composite combines desirable mechanical properties of polymers and the bioactivity of tissue or one or more component of tissue. More particularly, but not exclusively, the invention relates to methods for the... Agent: Krieg Devault LLP

20080069858 - Medical devices having biodegradable polymeric regions with overlying hard, thin layers: Implantable or insertable medical devices comprising a biodegradable polymeric region and a hard, thin layer disposed over the biodegradable polymeric region are described. Also described are methods for creating the same.... Agent: Mayer & Williams PC

20080069857 - Compositions and methods for inhibiting adhesions: The present invention provides compositions and methods for inhibiting adhesions. The methods involve administering solutions containing hydrogel precursors such as polysaccharide derivatives, e.g., derivatives of hyaluronic acid, cellulose, or dextran, to a subject at a site where adhesions may form, e.g., as a consequence of surgery, injury, or infection. The... Agent: Choate, Hall & Stewart LLP

20080069859 - Method for treating neovascularization and intravitreal implants: Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.... Agent: Birch Stewart Kolasch & Birch

20080069860 - Hyperphosphatemia in domestic animals: compositions and methods of treatment: The present invention is generally related to the treatment of hyperphosphatemia in domestic animals. It is specifically directed to compositions containing phosphate binders that are palatable to domestic animals and methods using such compositions. In a composition aspect, the present invention provides a composition that includes: a rare earth compound... Agent: Sheppard, Mullin, Richter & Hampton LLP

20080069861 - Probiotic/non-probiotic combinations: This invention pertains to a method of promoting gastrointestinal health by ingesting a composition comprising one or more probiotic microorganisms, one or more carbohydrate sources, and one or more resistant protein products. Large intestinal health is benefited by one or more of the following: increased fecal weight, lower fecal pH,... Agent: National Starch And Chemical Company

20080069862 - Joint preserving nutritional vitamin, mineral and herbal pet supplement: A pet supplement includes a joint preserving and joint rebuilding composition comprising chicken collagen type II, glucosamine hydrochloride and chondroitin sulfate, a vitamin composition comprising vitamins C, D and K, a mineral composition comprising calcium, magnesium, zinc, copper, manganese and boron, a herbal anti-oxidant cofactor blend comprising citrus bioflavonoids, red... Agent: Ernest D. Buff Ernest D. Buff And Associates, LLC.

20080069863 - Device for treatment of disorders in the oral cavity with nitric oxide, and manufacturing process for the same: A device and method for therapeutical treatment of disorders in the oral cavity and a process for manufacturing of said device is disclosed. The device comprises a nitric oxide (NO) eluting polymer. The nitric oxide (NO) eluting polymer is configured to elute a therapeutic dosage of nitric oxide (NO) when... Agent: Knobbe Martens Olson & Bear LLP

20080069864 - Delivery system for cosmetic and skincare products: Cosmetic and skin care products are dispersed or encapsulated within a polymer matrix to provide a convenient means of storing and transporting the cosmetic or skin care product prior to use. Prior to use the polymer matrix is solubilized or melted to release the cosmetic or skin care product to... Agent: Perman & Green

20080069865 - Controlled release cgrp delivery composition for cardiovascular and renal indications: The present invention provides methods of treating heart failure and improving renal function, and/or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The... Agent: Morrison & Foerster LLP

20080069866 - Immunotherapeutic methods and compositions: This invention relates to methods and compositions introducing chemical entities into antigen presenting cells. The resulting presentation of said antigens on the surface of the antigen presenting cells gives an effect on the immune system. The invention also relates to the resulting modified antigen presenting cells and pharmaceutical compositions containing... Agent: Ked & Associates, LLP

20080069867 - Diagnostic and/or remedy for ovarian cancer: It was found that an antibody containing the amino acid sequences described in the sequence listing as SEQ ID NOS: 1 to 6 was an antibody having reactivity also to ovarian cancer, as well as the cancer species known so far such as gastric cancer, colon cancer and breast cancer,... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069869 - Formulations and methods for modulating satiety: Formulations and methods of suppressing appetite and eliciting satiety in mammals are described. In some embodiments, oral administration of an effective amount of an appetite-suppressing peptide, in a composition that increases the bioavailability of the appetite-suppressing peptide, are effective to produce a feeling of satiety.... Agent: Mcdermott Will & Emery LLP

20080069868 - Irinotecan preparation: Provided is an irinotecan formulation capable of supporting irinotecan and/or a salt thereof in a closed vesicle carrier at a high concentration and existing in blood for a long period of time by dramatically improved retentivity in blood compared to a conventionally known irinotecan liposome formulation. That is, an irinotecan... Agent: Buchanan, Ingersoll & Rooney PC

20080069870 - Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection: The invention relates to a controlled release composition comprising a cephalosporin that in operation delivers the drug in a pulsed or bimodal manner for the treatment of bacterial infection. The controlled release composition comprises an immediate release component and a modified release component; the immediate release component comprising a first... Agent: Synnestvedt & Lechner LLP

20080069871 - Hydrophobic abuse deterrent delivery system: Disclosed herein are oral dosage forms of therapeutic agents that are resistant to abuse and methods of their formulation. In particular, oral dosage forms that are resistant to dissolution in aqueous solutions of ethanol are described.... Agent: Meyertons, Hood, Kivlin, Kowert & Goetzel, P.C.

20080069872 - Multi-layered controlled-release methylphenidate pellet: The present invention relates to a type of controlled-release multilayered methylphenidate pellet that does not need to be combined with another type of pellet. It allows the maintenance of therapeutic levels in the plasma during 12 hours with a single daily dose, avoiding repeated administrations throughout the day. The controlled-release... Agent: Sughrue Mion, PLLC

20080069873 - Controlled release system and method for manufacturing the same: The invention is directed to a pharmaceutical controlled release system for administration, particularly oral administration, of active substances with pH-dependent solubilities, comprising a) a core material containing or consisting of one or more pharmaceutically acceptable pH modifiers; b) optionally an insulating layer, c) a first layer containing or consisting of... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080069874 - Kits for prevention and treatment of rhinitis: Kits providing a combination of one or more pharmaceutical information comprising one or more agent(s) for the treatment or alleviation of symptoms commonly associated with a cold and an immunonutritional composition comprising immunonutritional agent and methods of using these kits are described . The kits provide both the pharmaceutical agent(s)... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080069876 - Method for preparing solid dosage forms that form a paste, cream or gel when diluted for final use: Solid compositions capable of forming a paste, cream or gel suitable for use as a personal hygiene product when diluted with a liquid are disclosed. Methods of making and using solid compositions capable of forming a paste, cream or gel suitable for use as a personal hygiene product when diluted... Agent: Withers & Keys, LLC

20080069875 - Disintegrating buccal tablets: Disintegrating buccal tablets comprising a physiologically active material and a polyvinyl alcohol/polyethylene glycol graft copolymer are disclosed along with methods of making the same.... Agent: Connolly Bove Lodge & Hutz, LLP

20080069877 - Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance: The present invention relates to a nutriceutical and/or pharmaceutical composition for oral use containing a calcium-containing compound. The composition is in the form of tablets that are designed so that they have an acceptable taste and mouthfeel, whereby the tablets are chewable or suckable, and at the same time the... Agent: Edwards Angell Palmer & Dodge LLP

20080069878 - Drug delivery systems comprising solid solutions of weakly basic drugs: The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric polymer, wherein the... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20080069879 - Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof: The present invention relates to stable solid dosage form and a dry process for preparing amorphous cefditoren pivoxil solid dosage forms and coating the solid dosage form with one or more layers of aqueous dispersion of film forming agents.... Agent: Jayadeep R. Deshmukh Ranbaxy Inc.

20080069880 - Enrobed core: An enrobed a core, such as a tablet core, that has a coating made of one or more patterned films each having portions that are visually distinct (e.g., differently colored) from one another and having a transition line segment between these visually distinct portions. At least a portion of an... Agent: Philip S. Johnson Johnson & Johnson

20080069881 - Abuse-resistant controlled-release opioid dosage form: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as... Agent: Ip Group Of Dla Piper US LLP

20080069882 - Novel preparation and administration form comprising an acid-labile active compound: Novel administration forms and preparation for acid-labile active compounds are described. The novel administration forms contain individual active compound units, the active compound being present in the active compound units in a matrix made of a mixture comprising at least one fatty alcohol and at least one solid paraffin, in... Agent: Nath & Associates PLLC

20080069884 - Amide derivatives of hyaluronic acid in osteoarthrosis: The present invention concerns amide derivatives of hyaluronic acid (HA) and biomaterials made of amide derivatives of hyaluronic acid (HA), particularly the hexadecylamide of HA, administered by the intraarticular route as a partial/total substitute for synovial fluid to treat joints affected by o steoarthrosis (OA) as well as cases of... Agent: Hedman & Costigan P.C.

20080069883 - Prostaglandin compositions and methods for the treatment of vasospasm: Compositions and methods for the treatment of vasospasm are provided comprising applying an amount of a semi-solid vasoactive prostaglandin composition to the affected tissue. Also provided are methods of improving microcirculation in a replanted body part.... Agent: Mirick, O'connell, Demallie & Lougee, LLP

20080069885 - Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles: Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release and a duration of action of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080069886 - Spironolactone nanoparticles, compositions and methods related thereto: This invention relates to nanoparticles comprising spironolactone. The nanoparticles have a mean diameter, measured by photon spectroscopy, in the range of from about 300 nm to about 900 nm.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080069887 - Method for nanoparticle surface modification: The present disclosure discloses a method for making surface-modified nanoparticles. The surface of a nanoparticle is modified with an aminorganosilane and an alkylating agent in a one-pot synthesis to provide alkylamine surface-modified nanoparticles.... Agent: 3m Innovative Properties Company

20080069888 - Modified release formulations of at least one form of tramadol: The present invention relates to a modified release composition of at least one form of tramadol which is a delayed and extended release composition for oral administration suitable for once daily dosing. That composition comprises a core comprising at least one form of tramadol selected from the group consisting of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080069889 - Compressible resilient granules and formulations prepared therefrom: The present invention provides resilient self-adhering granules which comprise a polysaccharide present in an amount from about 10 wt % to about 90 wt % and a binder having a viscosity from about 5,000 mPa·s to about 250,000 mPa·s present in an amount from about 90 wt % to about... Agent: Richard R. Muccino

20080069890 - Method for treating patients with implants of islets which have been kept in long term, in vitro culture: The invention relates to the use of macrobeads which have been kept in in vitro storage for long term culture, i.e., for at least about 8 months. The macrobeads surprisingly exhibit continued efficacy in producing therapeutically useful materials. The fact that the macrobeads can be used after long term culture... Agent: Fulbright & Jaworski, LLP

20080069891 - Abuse resistant drug formulation: A pharmaceutical composition may include a granulate which may include at least one active pharmaceutical ingredient susceptible to abuse by an individual mixed with at least two materials, a first material that is substantially water insoluble and at least partially alcohol soluble and a second material that is substantially alcohol... Agent: Cephalon, Inc.

20080069892 - Powder formulations: The present invention relates to powder formulations which consist of at least one agrochemical active substance, at least one polyurethane and/or polyurethane urea, and, if appropriate, additives and which have a particle diameter of less than 125 μm, to processes for the preparation of these formulations and to their use... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080069894 - Bioresorbable polymer matrices and methods of making and using the same: A bioerodible composition for delivery of a bioactive agent is the reaction product of a reaction mixture which includes an oxidized dextran solution, and a mixture of solids containing a dihydrazide, a bioactive agent, and optionally a pH adjusting agent in an amount sufficient to achieve a pH of the... Agent: Caroline Nash Nash & Titus, LLC

20080069893 - Compositions for repair of defects in osseous tissues, and methods of making the same: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues, and methods for making the same. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.... Agent: Morgan Lewis & Bockius LLP

20080069895 - Umbilical cord biomaterial for medical use: The present invention provides a biomaterial comprising a mammalian umbilical cord membrane. The biomaterial can additionally comprise Wharton's jelly and/or one or more umbilical cord vessels. The biomaterial is preferably dry, and can be flat, tubular, or shaped to fit a particular body structure. The invention further provides laminates comprising... Agent: Jones Day

20080069896 - Antitumor composition: Antitumor agents with high antitumor effect have much side-effect, and its activity decreases when the toxicity decreases. Thus, satisfactory antitumor effects are not always obtained. Therefore, development of an antitumor agent having a high antitumor effect, with less side-effect and low toxicity is awaited. The present invention is to provide... Agent: King & Spalding

20080069897 - Method for promoting and maintaining respiratory tract health: A method for promoting and maintaining respiratory tract health by moisturizing and cleansing a nasal membrane is disclosed. The method includes the steps of applying a drug-free, preservative-free composition to an interior portion of a nasal cavity using a spray applicator. The spray applicator includes a microbiological filter to prevent... Agent: Snell & Wilmer L.L.P. (main)

20080069898 - Topical compositions comprising myrica gale oil: The use of Myrica gale oil in the manufacture of a composition for the treatment of the skin or other exposed surfaces of the body is disclosed. Compositons prepared in accordance with the invention are particularly useful as anti-acne and anti-dandruff products. Myrica gale oil may bai used with other... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080069900 - Combination chemotherapy compositions and methods: This invention relates to combination therapies involving anticancer chemotherapeutic agents and isoflavones or analogues thereof. The invention flier relates to compounds, compositions, methods and therapeutic uses involving, containing, comprising, including and/or for preparing platinum-isoflavonoid complexes suitable for use in the combination therapies of the invention.... Agent: Sughrue Mion, PLLC

20080069902 - Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles: The invention provides a multi-arm block copolymer for use in delivering a variety of bioactive agents. The copolymer of the invention contains a central core from which extend multiple (3 or more) copolymer arms. Each copolymer arm possesses an inner polypeptide segment and an outer hydrophilic polymer segment. Thus, the... Agent: Nektar Therapeutics

20080069899 - Pharmaceutical compositions comprising beta-carboline derivatives and use thereof for the treatment of cancer: The invention relates to the use of at least one compound of general formula (1) for the production of a medicament for the treatment of cancer.... Agent: Young & Thompson

20080069901 - Therapeutic agent for metastatic cancer and cancer metastasis inhibitor: To provide a therapeutic agent for metastatic cancer and a cancer metastasis inhibitor which are highly safe and efficaciously treat metastatic cancer and inhibit cancer metastasis, and especially efficaciously treat and inhibit cancer metastasis to bone and liver. There are provided a therapeutic agent for metastatic cancer and a cancer... Agent: Sughrue Mion, PLLC

20080069903 - Electrical producing creams: New electrical producing creams are provided. In one embodiment, the electrical producing creams comprise menthol and camphor, preferably provided as part of a base gel, supplemented with potassium and a source of oxygen. The most preferred base gel is sold under the name SOMBRA. In another embodiment, the electrical producing... Agent: Hovey Williams LLP

20080069904 - Inhibition of angiogenesis through nitric oxide tachyphylaxis: A method is provided for treating cancer in a mammalian subject by inhibiting angiogenesis through the administration to the subject of a therapeutically effective amount of a nitrate-containing compound and a therapeutically effective amount of an inorganic selenium-containing compound. Kits and systems are also disclosed for practicing the subject methods.... Agent: David W. Collins - Intellectual Property Law

20080069905 - Device for application of medicaments, manufacturing method therefor, and method of treatment: A therapeutic treatment device is provided, which comprises a compound comprising a drug and a nitric oxide (NO) eluting polymer arranged to contact a treatment site in or on a body. The device is acting as a booster for drug eluting patches, e.g. pharmaceuticals, vitamins, nicotin, nitroglycerin, whereby with advantage... Agent: Knobbe Martens Olson & Bear LLP

20080069906 - Method and composition of a carminative herb or natural supplement to decrease the adverse effects of orlistat, and oral lipase inhibitor: A medicament to decrease the adverse events of Orlistat, an oral lipase inhibitor, arranged to be taken in combination with Orlistat, comprising: an admixture of carminative herbs and one or more chelating agents to absorb and mechanically agitate non-digested fats.... Agent: Donald N. Halgren

20080069907 - Compositions for cancer prevention, treatment, or amelioration comprising papaya extract: The components of a brew/extract of leaves or other parts of the papaya plant (Carica papaya) or fractionated components thereof are effective in the prevention or treatment of stomach cancer, lung cancer, pancreatic cancer, colon cancer or other solid cancers, or lymphoma, leukemia or other blood cancers, and are very... Agent: Sughrue Mion, PLLC

20080069908 - Compositions for safe and effective regression of dermal vessel tortuosity in psoriatic lesions: Topical compositions for Safe and Effective regression of Dermal Vessel Tortuosity in Psoriatic Lesions in the form of ointment, cream, oil, soap and shampoo contain non aqueous herbal extract of Wrightia Tinctoria, cocos nucifera, and suitable pharmaceutically/cosmetically accepted excipients for dermal use.... Agent: Bregen Technical Consultants L.L.C.

20080069909 - Menopause disorder synergistic phyto-nutraceutical composition: A Phytoceutical composition for the prevention and treatment of menopause disorders and symptoms is provided. A specific combination of extracts of plants is taught, as well as principles for varying the formulations based on categorizing plants into one of three groups, Energy, Bio-Intelligence, and Organization and selecting several plants from... Agent: Jose Olalde Rangel

20080069910 - Preventive, relieving or therapeutic composition for diabetes mellitus and/or diabetic nephropathy: To provide a composition for prevention, amelioration, or treatment of diabetes mellitus and/or diabetic nephropathy, which is less likely to cause any disadvantages such as side effects, and highly safe. [1] A composition for prevention, amelioration, or treatment of diabetes mellitus and/or diabetic nephropathy, containing one or more dietary fiber... Agent: Birch Stewart Kolasch & Birch

20080069911 - Plant extracts for the treatment of rheumatoid arthritis: The present invention provides a pharmaceutical composition comprising a crude extract or extract of Plectranthus Amboinicus (Lour.) Spreng (PA) for the treatment of rheumatoid arthritis. The present invention also provides a use of the crude extract or extract of Plectranthus Amboinicus (Lour.) Spreng for the manufacture of medicaments for treating... Agent: Ladas & Parry

20080069912 - Use of an acmella oleracea extract for the botox-like effect thereof in an anti-wrinkle cosmetic composition: Spilanthol, in the form of an Acmella oleracea extract, inhibits contractions in subcutaneous muscles, notably those of the face, and can be used as an anti-wrinkle product. A cosmetic treatment procedure for wrinkles consists of locally or subcutaneously applying an effective quantity of a composition based on spilanthol pure or... Agent: Heslin Rothenberg Farley & Mesiti PC

20080069913 - Anti-snoring composition: An anti-snoring composition including at least one lubricating substance and at least one bioadhesive substance which causes the lubricating substance to adhere to the mucocilliary cells located at pharynx level.... Agent: Ip Group Of Dla Piper US LLP

20080063599 - Compounds which can be used to diagnose and monitor diseases associated with the formation of amyloid protein fibrils: The invention relates to compounds having general formulae I, II and III, which can be used to diagnose and monitor diseases associated with the deposit of amyloid proteins in the central nervous system. The invention also relates to the use of the inventive compounds in the diagnosis of the aforementioned... Agent: Kramer & Amado, P.C.

20080063604 - Method and composition for the site-selective gene delivery using viruses: Methods and compositions for the site-selective delivery of a gene to a site within the body of an animal where virus not encapsulated within the microbubbles is inactivated, for example by treatment with a virus-inactivating agent.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20080063611 - Dentifrice compositions: Stain-removal, desensitizing, anti-tartar and anti-gingivitis dentifrice compositions. The dentifrices comprise a fluoride agent; an abrasive agent; a proteolytic agent; a foaming agent; a sweetening/flavoring agent; an emulsifying agent; either desensitizing, anti-tartar or anti-gingivitis agents or combinations thereof; and a delivery agent. The dentifrices are visually pleasing and impart a soothing... Agent: Crowell & Moring LLP Intellectual Property Group

20080063614 - Skin compositions containing hydrocortisone: Skin compositions comprising, hydrocortisone; allantoin; and a water-based vehicle that is essentially free of petroleum jelly, mineral oil and wax; and related method for protecting, healing and/or soothing the skin comprising: applying an effective amount of a cosmetic preparation selected from the group consisting of hand cream, foot cream, body... Agent: Dara L. Onofrio, Esq. C/o Onofrio Law

20080063615 - Color changing skin sealant: Iodine is used in about 80 percent of surgeries in the US to remove some level of microbial load on the skin prior to making an incision. Skin sealants are applied over skin preps to seal the skin and hold any remaining bacteria in place. Iodine produces a characteristic orange-brown... Agent: Kimberly-clark Worldwide, Inc. Catherine E. Wolf

20080063616 - Antiperspirant compositions and methods for making same: A consumer product comprising packaging including a product chamber and an outer jacket at least partially surrounding the product chamber; and an antiperspirant composition disposed within the product chamber, wherein the composition exhibits an average standard deviation of less than or equal to about 5 of penetration peak force measurements... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080063619 - Cosmetic compositions with ethylene brassylate: A cosmetic composition is provided which includes tapioca starch and ethylene brassylate in a cosmetically acceptable carrier. The composition provides a silky afterfeel to skin.... Agent: Unilever Intellectual Property Group

20080063617 - Cosmetics formulations: A cosmetic formulation containing an alkylated chitosan derivative, a polybasic carboxylic acid or an oxidized polysaccharide, and water, for moisturizing and/or softening skin is provided. The formulation is in the physical state of a viscous liquid or a gel, and when applied to skin, serves to moisturize and soften the... Agent: Schwegman, Lundberg & Woessner, P.A.

20080063623 - Avian cytokines, such as il-12, comprising a p40 and/or p35 subunit and vaccines: Embodiments of the present invention generally relate to novel avian cytokines, to DNA sequences encoding these novel cytokines and to their use in adjuvants for vaccine purposes.... Agent: Intervet Inc. Patent Department

20080063628 - Methods to promote cell differentiation: A method for promoting the differentiation of cells by contacting cells with a chromatin-remodeling agent to increase the expression of a transcriptional regulator.... Agent: Philip S. Johnson Johnson & Johnson

20080063627 - Tissue graft materials containing biocompatible agent and methods of making and using same: The invention provides implantable tissue graft materials composed of a collagenous tissue scaffold and a biocompatible agent bonded to the tissue scaffold via an activated photoreactive group. The invention further provides methods including steps of obtaining a tissue graft material comprising a collagenous tissue scaffold; contacting the collagenous tissue scaffold... Agent: Kagan Binder, PLLC

20080063598 - Humanized antibody: Novel humanized and chimeric antibodies, humanized antibody fragments, polypeptides sequences of such antibodies and derivatives thereof that specifically bind AF-20 are provided as well as methods for their manufacture. These humanized and chimeric antibodies, antibody fragments and polypeptide sequences are useful in the treatment of cancers that express AF-20, as... Agent: Goodwin Procter LLP

20080063600 - Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissued derived products: B-cells have been identified as being the crucial carriers of infectivity in the spread of transmissible spongiform encephalopathy within an infected organism. In a second step, B-cells may infect further components_of the immune system, e.g. T-cells. Accordingly, the present invention provides B-cell and T-cell specific ligands for the use in... Agent: Dykema Gossett PLLC

20080063601 - Compositions and methods relating to polycystic kidney disease: Described herein are therapeutic strategies (methods and compositions) useful for treating conditions in which cilia are affected and which manifest with cysts and/or fibrosis, such as conditions in which the kidney, pancreas, liver and/or spleen are affected and contain cysts. Particular embodiments described herein are therapeutic strategies in which PC-2... Agent: Wolf Greenfield & Sacks, P.C.

20080063602 - Magnetic resonance imaging contrast agents synthesized using ring-opening metathesis polymerization: Polymeric chelating agents and metal chelates, particularly those of lanthanide metals and more specifically those of Gd(III), useful as contrast agents in magnetic resonance imaging (MRI) for therapeutic and diagnostic applications as well as clinical and biomedical research applications. The polymeric chelates are generated using ring-opening metathesis polymerization (ROMP). Polymers... Agent: Greenlee Winner And Sullivan P C

20080063605 - Method of enhancing visualization of atherosclerotic plaque: The invention relates to a method and a corresponding device for multipurposely supporting a randomly shaped and/or possibly complex with respect to a rigid base (11) part (1) by fixing a working reference, wherein the inventive method consist in interposing at least one deformable constant-volume chamber (3) which is sealed... Agent: Wilson Sonsini Goodrich & Rosati

20080063603 - Ultrasound contrast agents and methods of making and using them: The invention is directed to injectable suspensions of gas-filled microvesicles, as well as methods of preparing and using the same, especially as ultrasound contrast agents.... Agent: Kramer Levin Naftalis & Frankel LLP

20080063606 - Pulmonary delivery of aminoglycoside: A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.... Agent: Nektar Therapeutics

20080063607 - Oleaginous pharmaceutical and cosmetic foam: The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent... Agent: Wilmerhale/boston

20080063608 - Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid, and betamimetic: wherein X− is an anion with a single negative charge; (b) a corticosteroid; and (c) a betamimetic, wherein each component (a), (b), and (c) are optionally in the form of the solvates or hydrates thereof, processes for preparing them, and their use in the treatment of respiratory diseases.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080063609 - Compressed chewing gum tablet: The invention relates to a chewing gum tablet (20) comprising at least two cohered chewing gum modules (21, 22, 23), said tableted chewing gum being formed by compression of chewing gum granules, at least one of said chewing gum modules comprising gum base granules, said gum base granules comprising an... Agent: Cantor Colburn, LLP

20080063610 - Use of beta-homocyclocitral as an agent against bad breath: The use of beta-homocyclocitral is described as an agent (i) to inhibit and/or prevent the growth of and/or to destroy micro-organisms causing bad breath and/or (ii) to combat bad breath.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20080063612 - Dental whitening compositions: A two-component whitening system has a de-sensitizing effect as well as re-mineralizing capability. The system may be an unfoamed, a foamed or a foamable composition. The system has a first component with at least one peroxide compound, at least one source of phosphate and at least one gelling agent; and... Agent: Discus Dental Impressions, Inc.

20080063613 - Syndet bars having ultraviolet radiation protection: The present invention is drawn to a syndet soap bar that after the washing process leaves a residual deposit on a substrate that provides protection from ultraviolet radiation comprising (a) a non-emulsifying surfactant having an HLB greater than 15; (b) from greater than 10% to about 25% by weight red... Agent: Louis C. Paul Louis C. Paul & Associates

20080063618 - Personal care compositions comprising a zinc containing material in an aqueous surfactant composition: Disclosed are compositions comprising an effec